ALX Oncology (ALXO) Competitors $0.41 -0.02 (-4.62%) Closing price 04:00 PM EasternExtended Trading$0.40 0.00 (-0.98%) As of 04:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ALXO vs. IMUX, ZNTL, KYTX, ORMP, ANIX, CLLS, CLYM, SNTI, GALT, and ADAGShould you be buying ALX Oncology stock or one of its competitors? The main competitors of ALX Oncology include Immunic (IMUX), Zentalis Pharmaceuticals (ZNTL), Kyverna Therapeutics (KYTX), Oramed Pharmaceuticals (ORMP), Anixa Biosciences (ANIX), Cellectis (CLLS), Climb Bio (CLYM), Senti Biosciences (SNTI), Galectin Therapeutics (GALT), and Adagene (ADAG). These companies are all part of the "pharmaceutical products" industry. ALX Oncology vs. Immunic Zentalis Pharmaceuticals Kyverna Therapeutics Oramed Pharmaceuticals Anixa Biosciences Cellectis Climb Bio Senti Biosciences Galectin Therapeutics Adagene ALX Oncology (NASDAQ:ALXO) and Immunic (NASDAQ:IMUX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, community ranking, institutional ownership, risk, earnings, valuation, media sentiment and analyst recommendations. Do analysts recommend ALXO or IMUX? ALX Oncology currently has a consensus target price of $3.30, suggesting a potential upside of 706.85%. Immunic has a consensus target price of $13.20, suggesting a potential upside of 1,334.78%. Given Immunic's stronger consensus rating and higher probable upside, analysts plainly believe Immunic is more favorable than ALX Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ALX Oncology 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.71Immunic 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.25 Does the MarketBeat Community believe in ALXO or IMUX? Immunic received 55 more outperform votes than ALX Oncology when rated by MarketBeat users. However, 65.52% of users gave ALX Oncology an outperform vote while only 65.50% of users gave Immunic an outperform vote. CompanyUnderperformOutperformALX OncologyOutperform Votes5765.52% Underperform Votes3034.48% ImmunicOutperform Votes11265.50% Underperform Votes5934.50% Does the media prefer ALXO or IMUX? In the previous week, Immunic had 2 more articles in the media than ALX Oncology. MarketBeat recorded 4 mentions for Immunic and 2 mentions for ALX Oncology. Immunic's average media sentiment score of 0.75 beat ALX Oncology's score of -0.50 indicating that Immunic is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ALX Oncology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative Immunic 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders believe in ALXO or IMUX? 98.0% of ALX Oncology shares are held by institutional investors. Comparatively, 51.8% of Immunic shares are held by institutional investors. 33.4% of ALX Oncology shares are held by company insiders. Comparatively, 3.0% of Immunic shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has more risk & volatility, ALXO or IMUX? ALX Oncology has a beta of 1.21, suggesting that its share price is 21% more volatile than the S&P 500. Comparatively, Immunic has a beta of 1.73, suggesting that its share price is 73% more volatile than the S&P 500. Is ALXO or IMUX more profitable? ALX Oncology's return on equity of -93.02% beat Immunic's return on equity.Company Net Margins Return on Equity Return on Assets ALX OncologyN/A -93.02% -70.67% Immunic N/A -169.55%-118.96% Which has preferable earnings and valuation, ALXO or IMUX? Immunic is trading at a lower price-to-earnings ratio than ALX Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioALX OncologyN/AN/A-$160.80M-$2.47-0.17ImmunicN/AN/A-$93.61M-$1.23-0.75 SummaryImmunic beats ALX Oncology on 10 of the 16 factors compared between the two stocks. Get ALX Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for ALXO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALXO vs. The Competition Export to ExcelMetricALX OncologyPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$21.84M$6.49B$5.36B$8.39BDividend YieldN/A2.66%5.22%4.10%P/E Ratio-0.148.9426.5919.72Price / SalesN/A251.55391.61116.20Price / CashN/A65.8538.2534.62Price / Book0.116.466.794.51Net Income-$160.80M$143.98M$3.23B$248.18M7 Day Performance-10.97%3.16%4.03%1.14%1 Month Performance-27.76%7.60%12.22%15.07%1 Year Performance-97.00%-2.36%16.76%6.59% ALX Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALXOALX Oncology3.3974 of 5 stars$0.41-4.6%$3.30+706.8%-96.9%$21.84MN/A-0.1440Analyst ForecastIMUXImmunic2.5844 of 5 stars$0.960.0%$13.20+1,274.0%-24.5%$92.05MN/A-0.7870Earnings ReportGap DownZNTLZentalis Pharmaceuticals1.9616 of 5 stars$1.25-0.8%$8.24+559.6%-89.1%$89.94M$67.43M-0.50160News CoverageEarnings ReportAnalyst RevisionKYTXKyverna Therapeutics2.3955 of 5 stars$2.07-10.8%$18.33+785.7%-83.4%$89.46M$7.03M-0.6196News CoverageAnalyst RevisionGap DownORMPOramed Pharmaceuticals1.7805 of 5 stars$2.14-0.5%N/A-9.3%$87.42M$1.34M19.4510Earnings ReportANIXAnixa Biosciences1.7561 of 5 stars$2.70+1.9%$9.00+233.3%-8.1%$86.93M$210,000.00-6.925CLLSCellectis2.7553 of 5 stars$1.55-1.9%$6.67+330.1%-48.1%$86.16M$47.63M-1.19290CLYMClimb Bio2.5919 of 5 stars$1.27-1.6%$10.00+687.4%N/A$85.82MN/A-0.609News CoverageEarnings ReportAnalyst RevisionSNTISenti Biosciences1.7169 of 5 stars$3.24+1.9%$12.00+270.4%-14.9%$84.50M$2.56M-0.214GALTGalectin Therapeutics1.2377 of 5 stars$1.33+3.9%$11.00+727.1%-59.2%$84.03MN/A-1.829Earnings ReportADAGAdagene2.3476 of 5 stars$1.77flat$8.00+352.0%-40.0%$83.39M$103,204.000.00260 Related Companies and Tools Related Companies Immunic Competitors Zentalis Pharmaceuticals Competitors Kyverna Therapeutics Competitors Oramed Pharmaceuticals Competitors Anixa Biosciences Competitors Cellectis Competitors Climb Bio Competitors Senti Biosciences Competitors Galectin Therapeutics Competitors Adagene Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALXO) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ALX Oncology Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ALX Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ALXO Stock Free ALXO Stock Alerts